NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing special purpose nanomaterials for antiviral therapy, announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses has begun enrolling and dosing patients at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo. The trial’s Phase IIA portion, which started enrollment and dosing around Sept. 23, is designed to establish a safe and well-tolerated NV-387 dosing protocol; that protocol will then be used in the Phase IIB portion to evaluate safety, tolerability and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077.
This development matters because Ebola outbreaks, particularly those caused by the Bundibugyo strain, have historically been difficult to contain and treat, with limited therapeutic options. An oral, broad-spectrum antiviral could be a game-changer in outbreak settings where intravenous administration is impractical. NV-387 is being developed as a broad-spectrum antiviral with potential applications beyond Ebola, including RSV, COVID, Long COVID, Influenza, MPOX/Smallpox and Measles. If successful, the trial could validate NanoViricides’ nanoviricide platform, which is based on intellectual property from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several human viral diseases, including Ebola/Marburg viruses. For investors, the start of patient dosing represents a significant milestone, moving NV-387 from preclinical promise into human efficacy testing. More details are available in the full press release at https://ibn.fm/qC4Hk.
The trial’s progression will be closely watched, as positive results could pave the way for NV-387 to become a first-line defense against Ebola and other emerging viral threats. NanoViricides’ business model focuses on licensing technology from TheraCour Pharma Inc. for specific application verticals, and the company’s pipeline includes NV-HHV-1 for Shingles and NV-CoV-2 for COVID-19. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. For more information about NanoViricides, visit www.nanoviricides.com.
The announcement was disseminated through MissionIR, a specialized communications platform that assists IR firms with syndicated content. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. As with any drug development effort, there can be no assurance that NanoViricides’ pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
